KCNQ2 Antibody (E-6): sc-365114
- KCNQ2 Antibody (E-6) is a mouse monoclonal IgG2b κ provided at 200 µg/ml
- raised against amino acids 641-780 mapping near the C-terminus of KCNQ2 of human origin
- recommended for detection of KCNQ2 of mouse, rat and human origin by WB, IP, IF and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for KCNQ2 Antibody (E-6). This work is in progress.
QUICK LINKS
SEE ALSO...
KCNQ2 Antibody (E-6) is a mouse monoclonal IgG2b antibody that detects KCNQ2 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). KCNQ2 is a voltage-gated potassium channel that plays a crucial role in regulating neuronal excitability and maintaining the resting membrane potential, which is vital for proper electrical signaling in the central nervous system. Mutations in the KCNQ2 gene can lead to benign familial neonatal convulsions, highlighting KCNQ2′s importance in epilepsy and other neurological disorders. KCNQ2 is characterized by six transmembrane domains, which contribute to function as a potassium ion channel, allowing for selective passage of potassium ions across the cell membrane. This selective permeability is essential for repolarizing the neuronal membrane after action potentials, thereby preventing excessive neuronal firing and maintaining the balance of excitatory and inhibitory signals in the brain. Anti-KCNQ2 antibody (E-6) is an invaluable tool for researchers studying molecular mechanisms underlying epilepsy and other related conditions, providing insights into the role of potassium channels in neuronal function and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
KCNQ2 Antibody (E-6) References:
- Molecular basis for ligand activation of the human KCNQ2 channel. | Li, X., et al. 2021. Cell Res. 31: 52-61. PMID: 32884139
- Capturing seizures in clinical trials of antiseizure medications for KCNQ2-DEE. | Millichap, JJ., et al. 2021. Epilepsia Open. 6: 38-44. PMID: 33681646
- Flexible Stoichiometry: Implications for KCNQ2- and KCNQ3-Associated Neurodevelopmental Disorders. | Springer, K., et al. 2021. Dev Neurosci. 43: 191-200. PMID: 33794528
- KCNQ2 gene mutations and neonatal epilepsy. | García Castellanos, MT., et al. 2021. Med Clin (Barc). 157: 589-590. PMID: 33962768
- KCNQ2 and KCNQ5 form heteromeric channels independent of KCNQ3. | Soh, H., et al. 2022. Proc Natl Acad Sci U S A. 119: e2117640119. PMID: 35320039
- Pyridoxine-responsive KCNQ2 epileptic encephalopathy: Additional cases and literature review. | Chen, J., et al. 2022. Mol Genet Genomic Med. 10: e2024. PMID: 35906921
- KCNQ2 Encephalopathy and Responsiveness to Pyridoxal-5'-Phosphate. | Chow, CK., et al. 2023. J Pediatr Genet. 12: 90-94. PMID: 36684546
- Clinical analysis and functional characterization of KCNQ2-related developmental and epileptic encephalopathy. | Ye, J., et al. 2023. Front Mol Neurosci. 16: 1205265. PMID: 37497102
- KCNQ2/3 Gain-of-Function Variants and Cell Excitability: Differential Effects in CA1 versus L2/3 Pyramidal Neurons. | Varghese, N., et al. 2023. J Neurosci. 43: 6479-6494. PMID: 37607817
- A small-molecule activation mechanism that directly opens the KCNQ2 channel. | Zhang, S., et al. 2024. Nat Chem Biol. 20: 847-856. PMID: 38167918
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
KCNQ2 Antibody (E-6) | sc-365114 | 200 µg/ml | $316.00 |